Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies
Vandana SinghBenzinga Staff Writer November 17, 2026, 12:18 PM ETNov 17, 12:18 PM ET3 min read3 min
LLYEli Lilly and Co
$1410.72-1.46%
Eli Lilly and Co. (NYSE:LLY) entered a strategic research collaboration and licensing agreement with privately held biotechnology company Stipple Bio Inc. on Monday to develop targeted cancer therapies.
The agreement covers multiple drug targets and therapeutic approaches, with Stipple Bio eligible to receive up to $5.9 billion in milestone payments, along with royalties on potential product sales.
Deal Terms
Under the agreement, Stipple Bio will receive an upfront payment and an equity investment from Eli Lilly.…